Stand A1
Pall corporation offers integrated end-to-end bioprocessing solutions for gene therapy, from early process development projects to commercialization. Our dedicated experts will work with you to overcome development and viral vector manufacturing obstacles to accelerate delivery of commercially viable gene therapies to patients. Our extensive portfolio of upstream, downstream, and formulation and filling technologies is suitable for manufacturing different viral vector types in adherent or suspension-based processes. Whether that means quickly developing a process, helping you ensure regulatory compliance, or making existing processes easier and more effective, we are ready to work with you to accelerate your speed to market.